Lipitor, a brand name for atorvastatin, is a cholesterol-lowering medication prescribed to reduce the risk of cardiovascular disease [1]. To ensure safe and effective treatment, patients often need to monitor their Lipitor levels. The frequency of checking Lipitor levels depends on several factors, such as the patient's medical condition, other medications they are taking, and their individual response to the medication.
Typically, patients on Lipitor therapy should have their blood lipid levels checked before starting treatment, at 4-6 weeks after starting therapy, and every 6-12 months thereafter [2]. However, if the patient has a significant change in their medical condition, such as a kidney or liver problem, or if they are taking other medications that interact with Lipitor, they may need closer monitoring.
One study found that patients on statin therapy, including Lipitor, had a significant decline in cardiovascular risk when their LDL-C levels were reduced to < 70 mg/dL [3]. Another study suggested that tighter lipid control, achieved by measuring and monitoring Lipitor levels, can significantly reduce cardiovascular events in high-risk patients [4].
It is essential to note that Lipitor levels should be measured at a laboratory that has been certified to perform the test by a national accrediting agency, such as the College of American Pathologists [5]. Additionally, patients should inform their healthcare provider of any medication changes or new prescription medications they are taking.
The recommended blood lipid profiles to check while on Lipitor therapy include:
- Total cholesterol
- LDL-C (bad cholesterol)
- HDL-C (good cholesterol)
- Triglycerides
For more information on Lipitor levels and lipid monitoring, DrugPatentWatch.com provides a list of available generic versions and patient advice.
Sources:
[1] https://www.drugs.com/lipitor.html
[2] https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/proper-use/drg-20073211
[3] LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease. N Engl J Med 2005;352:1425-35.
[4] Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
[5] https://www.cap.org/
DrugPatentWatch.com: https://www.drugpatentwatch.com/